DNA breaks in P288 tumor cells in mice after treatment with daunorubicin and adriamycin.
Extensive DNA damage was found in tumor cells after therapeutic doses of daunorubicin and adriamycin (2.5 - 10 mg/kg) were administered to mice bearing lymphocytic leukemia (P-288). After low doses (0.6 mg/kg), DNA breaks were evident as early as 1-3 hr after daunorubicin and as determined with adriamycin the damage lasted as long as 72 hr. In a comparison, actinomycin D produced smaller amounts of damage by 3 hr after the administration of maximally tolerated doses (0.8 mg/kg) and even less after 0.4 mg/kg. These experiments indicate that the antitumor activity of daunorubicin and adriamycin in treated mice may result from damage to the cellular DNA.
D000818:Animals; D002250:Carbon Radioisotopes; D002478:Cells, Cultured; D002499:Centrifugation, Density Gradient; D004273:DNA, Neoplasm; D003609:Dactinomycin / Q000627:therapeutic use; D003630:Daunorubicin / Q000494:pharmacology* / Q000627:therapeutic use; D004317:Doxorubicin / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D007945:Leukemia, Lymphoid / Q000188:drug therapy / Q000378:metabolism*; D051379:Mice; D008815:Mice, Inbred Strains; D009368:Neoplasm Transplantation; D009691:Nucleic Acid Denaturation; D013395:Sucrose; D013997:Time Factors; D014184:Transplantation, Homologous; D014316:Tritium
D002250:Carbon Radioisotopes; D004273:DNA, Neoplasm; D014316:Tritium; D003609:Dactinomycin; D013395:Sucrose; D004317:Doxorubicin; D003630:Daunorubicin